MedTrace Logo

Clinical Trial Comparing Pain Perception in Children Using Two Different Local Anesthesia Tools

NCT07292194 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical study is to learn whether the Super Pen (SP) device can reduce pain during local anesthesia (LA) infiltration for primary teeth compared to the conventional syringe (CS) in children aged 6-12 years. It will also explore factors that influence children's pain perception and their preferences for the anesthesia delivery method.

The main questions this study aims to answer are:

* Does the Super Pen (SP) reduce the pain experienced during LA infiltration compared to the conventional syringe (CS)?
* How do factors such as age, sex, and arch treated (maxilla or mandible) influence children's pain perception when using the SP?
* Which method-SP or CS-do children prefer during LA infiltration?

Participants will:

Receive local anesthesia using both the SP and CS techniques in a split-mouth design.

Have their pain responses assessed using self-reported, behavioral, and physiological measures.

Indicate their preference for either technique after both experiences.

Conditions

  • Injection Pain
  • Local Anesthesia Infiltration
  • Pediatric Patient

Interventions

DEVICE

super pen

computer controlled local anesthesia delivery device

Sponsors & Collaborators

  • Lamis D. Rajab

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-04-01
Completion
2026-04-01

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292194 on ClinicalTrials.gov